5-chloro-1-(4-chloro-benzyl)-1H-indazole-3-carboxylic acid | 50264-67-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 5-chloro-1-(4-chloro-benzyl)-1H-indazole-3-carboxylic acid
• 英文别名: 1H-Indazole-3-carboxylic acid, 5-chloro-1-[(4-chlorophenyl)methyl]-；5-chloro-1-[(4-chlorophenyl)methyl]indazole-3-carboxylic acid
• CAS: 50264-67-0
• 化学式: C₁₅H₁₀Cl₂N₂O₂
• 分子量: 321.163
• InChiKey: JLBZZQZPUSAOTE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Lonidamine analogs
  申请人：Matteucci Mark

  公开号：US20070015771A1

  公开（公告）日：2007-01-18

  Lonidamine analogs are useful in the treatment and prevention of cancer, benign prostatic hyperplasia, macular degeneration and prostatic intraepithelial neoplasia, or for use as an antispermatigenic agent.

  Lonidamine类似物在治疗和预防癌症、良性前列腺增生、黄斑变性和前列腺上皮内瘤变方面非常有用，或者用作抗精子生成剂。
• [EN] MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS<br/>[FR] MODULATEURS DU RÉCEPTEUR X4 DE LA PROTÉINE G ASSOCIÉE À MAS ET PRODUITS ET PROCÉDÉS ASSOCIÉS
  申请人：[en]ESCIENT PHARMACEUTICALS, INC.

  公开号：WO2022061008A2

  公开（公告）日：2022-03-24

  Methods are provided for modulating MRGPR X4 generally, or for treating a MRGPR X4-dependent condition more specifically, by contacting MRGPR X4 or administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I): or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein E, Q, W, Z, R1, R2, R3, and R4are as defined herein. Pharmaceutical compositions containing such compounds, as well as compounds themselves, are also provided.